Introduction {#Sec1}
============

Ventilation of ARDS patients with low tidal volume (Vt) is performed in order to minimize ventilation induced lung injury. This strategy, however, may induce hypercapnic acidosis, promote derecruitment and, in some individuals, induce alveolar overdistention despite the use of low Vt. Extracorporeal CO~2~ removal can help minimizing hypercapnic acidosis and to further reduce Vt (i.e. *ultraprotective* ventilation).

Objectives {#Sec2}
==========

To evaluate the effect of extracorporeal CO~2~ removal in ARDS during *ultraprotective* ventilation in terms of lung mechanics and gas exchange.

Methods {#Sec3}
=======

We studied 9 ARDS patients, in whom *ultraprotective* ventilation (i.e. Vt 4 ml/kg PBW) was implemented by means of an extracorporeal CO~2~ removal system \[Hemolung^®^ Respiratory Assist System (RAS), ALung, Pittsburgh\]. Anticoagulation with unfractionated heparin to reach an aPTT target range of 1.5-2 was used. We compared baseline ventilation with *ultraprotective* ventilation (combining Vt of 4 ml/kg PBW and Hemolung^®^), in terms of lung mechanics and gas exchange. We collected arterial blood gases, respiratory and hemodynamic variables, and mixed expired gases at baseline and after 60 minutes of stabilization at *ultraprotective* ventilation. Statistical analysis: 2-tailed Student\'s t-test. Statistical significance p \< 0.05.

Results {#Sec4}
=======

Five men and four women with ARDS where studied (8 pneumonias and 1 abdominal sepsis). Age was 61 ± 14 years, SAPS II at admission 48 ± 28 and ICU mortality 22% (2/9). Seven of these patients were treated with prone positioning during mechanical ventilation. Cannulation was done via femoral vein in all patients, using "ad hoc" 15.5 Fr catheters. Hemolung^®^ allowed a CO~2~ removal rate of 84 ± 9 mL/min, with blood flow 447 ± 35 mL/min, at constant sweep gas flow (10 L/min of O~2~) and pump speed (1400 RPM). Unfractionated heparin dose was 200 ± 78 mg/day and aPTT was 1,56 ± 0.18. During catheter insertion a bolus of 0.6 ± 0.2 mg/kg mg was administered. Hemolung^®^ total days were 5.3 ± 6.2 (range 1 to 22). No significant haemorrhage or hemolysis needing transfusion, device malfunction, insertion and/or withdrawal complications occurred. We report a significant reduction in minute ventilation and alveolar minute ventilation (75% and 66%, respectively), dead space (68%), and driving pressure (69%), without significant changes in arterial blood gases when *ultraprotective* strategy was implemented, as compared to baseline (see tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1VARIABLEBASELINE4ml/kg PBW + Hemolung®T-TEST pVt (mL/kg PBW)6.4 ± 14 ± 0\< 0.001Vt (mL)374 ± 55238 ± 47\< 0.001RR (bpm)24 ± 328 ± 60.027VE (ml/min) \[=Vt\*RR\]8798 ± 12976639 ± 16790.004PEEP (cmH2O)11 ± 113 ± 40.227Pplat (cmH2O)24 ± 422 ± 30.074Crs (mL/cmH2O) \[=Vt/Pplat-PEEP\]30 ± 930 ± 110.998ΔP \[cmH2O\] \[=Pplat-PEEP\]13 ± 39 ± 60.003Table 2VARIABLEBASELINE4ml/kg PBW + Hemolung®T-TEST pVd (mL) \[=(PaCO2-PECO2/PaCO2\]262 ± 29175 ± 27\< 0.001Vd/Vt0.71 ± 0.060.75 ± 0.090.219Va min (mL/min) \[=(Vt-Vd)\*RR\]2614 ± 7711718 ± 8560.028FiO20.6 ± 0.20.6 ± 0.10.420pH7.38 ± 0.067.35 ± 0.110.493PaO2 (mmHg)91 ± 21109 ± 280.138PaCO2 (mmHg)50 ± 1949 ± 120.919MAP (mmHg)79 ± 1875 ± 140.332HR (bpm)101 ± 2692 ± 220.048

Conclusions {#Sec5}
===========

Hemolung^®^ system allows *ultraprotective* ventilation, while maintaining adequate arterial blood gases and significantly decreasing the intensity of ventilator assistance. The technique appears to be useful and safe.
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